AI aims to help babies born addicted to opioids

NCT ID NCT06303986

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Rekovar Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study gathers health data from 100 newborns, some with neonatal abstinence syndrome (NAS) and some healthy, to train an artificial intelligence system. The goal is to create a tool that automatically scores NAS symptoms using continuous monitoring, reducing human bias and improving care. The research does not test any drug or treatment, only collects information for future AI development.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a more objective, automated way to monitor and treat newborns with NAS, potentially reducing hospital stays.
What could go wrong: This is an early data-collection study, not a treatment trial. The AI algorithm may not perform as expected, and results may not apply to all hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEONATAL ABSTINENCE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neonatal abstinence syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEONATAL ABSTINENCE SYNDROME

Contacts and locations

Locations

University of New Mexico

Albuquerque, New Mexico, 87106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.